Prof. Jean de la Rosette
3
reviews
The doctors and staff were professional and attentive.
Our interpreter Amina was excellent and accompanied us throughout every stage.
29/06/2025
It is one of the cleanest and most modern hospitals, with staff who are always ready to help.
The team is always smiling, friendly and goes the extra mile for patients.
29/04/2024
I was very well taken care of and guided through all the legal and medical procedures.
The staff is wonderful and literally everyone was very friendly.
29/04/2023
Prof. Jean de la Rosette is a urologist with more than thirty years of international experience and one of the strongest academic reputations in modern urology: more than 750 scientific publications, an h-index of 113, and over 55,000 citations to his work. Since 2024 he has been President of the Société Internationale d’Urologie (SIU), having previously served six years as its Secretary General. He founded and led CROES, the research office of the Endourological Society, and helped establish the Uro-Technology section of the European Association of Urology. Before moving to Istanbul, he chaired the Department of Urology at Amsterdam UMC (Netherlands) for 16 years. His clinical focus covers minimally invasive prostate and kidney surgery, endourology, focal therapy of prostate cancer (including irreversible electroporation), ultrasound and tomographic diagnostics in urology, and the treatment of benign prostatic hyperplasia and urolithiasis. For the patient, choosing him means access to treatment by one of Europe’s most authoritative urologists at an internationally accredited clinic.
Achievements and Awards
About Dr. Jean de la Rosette
- minimally invasive urological surgery;
- endourology;
- ablative treatment methods (including irreversible electroporation for prostate cancer);
- focal therapy for prostate cancer;
- ultrasound and tomographic diagnostics in urology;
- benign prostatic hyperplasia;
- urolithiasis.
- Until 1992 — medical degree and residency in urology at St Radboud University Hospital, Nijmegen (Netherlands).
- 1992–2002 — urologist at St Radboud University Hospital, Nijmegen (Netherlands).
- 2002–2018 — Professor and Chair of the Department of Urology at Amsterdam UMC (Netherlands).
- Since 2018 — Professor of Urology at Istanbul Medipol University, practising at Medipol Mega University Hospital (Istanbul).
- Since 2025 — additional professorship at Bashkir State Medical University (Ufa, Russia).
- More than 750 scientific publications in peer-reviewed journals; h-index of 113; more than 55,000 citations on Google Scholar.
- Founder and head of CROES, the research office of the Endourological Society.
- Member of several expert committees of the International Consultation on Urological Diseases (ICUD): on minimally invasive treatment of benign prostatic hyperplasia, on upper urinary tract tumours; co-chair of the committee on urolithiasis.
- Main research areas: focal therapy for prostate cancer, irreversible electroporation, treatment of benign prostatic hyperplasia, urolithiasis.
- Publications in European Urology, World Journal of Urology, Journal of Endourology, BJU International, The Journal of Urology.
- Société Internationale d’Urologie (SIU) — President (since 2024), former Secretary General (2016–2022).
- Endourological Society — board member (1996–2016); founder and chair of the CROES research office.
- European Association of Urology (EAU) — co-founder of the Section of Uro-Technology (ESUT); founder and chair of the clinical guidelines working group on benign prostatic hyperplasia.
- International Consultation on Urological Diseases (ICUD) — member of several expert committees.
Medipol Mega University Hospital is a university clinic that combines a complex of four specialised hospitals under one roof: general, oncology, cardiac surgery and dental. The hospital holds international JCI accreditation and was the first in Turkey to receive separate JCI Academic Medical Center accreditation. The clinic runs a robotic surgery programme (da Vinci system) in urology, cardiac surgery, gynaecology and general surgery, as well as High-Intensity Focused Ultrasound (HIFU) technology for the treatment of prostate cancer, uterine fibroids and bone metastases. The dedicated oncology hospital within the complex hosts multidisciplinary tumour boards. For a patient with prostate cancer, benign prostatic hyperplasia or urolithiasis, this means the opportunity to undergo diagnostics, robotic or endoscopic surgery, and post-operative follow-up at an internationally accredited university clinic.
